Loading
A phase 2 trial of Tislelizumab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by BeiGene, active and no longer recruiting.
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05635708 by BeiGene, with 400 participants planned, started 2023-03-07 and due to reach its primary completion in 2025-12-31. Interventions recorded: Tislelizumab, BGB-A445, LBL-007, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Tislelizumab, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.